Oncolytic herpes simplex virus vectors for the treatment of human breast cancer.

Abstract

BACKGROUND:

Oncolytic herpes simplex virus (HSV) vectors can be used for cancer therapy as direct cytotoxic agents, inducers of anti-tumor immune responses, and as expressers of anti-cancer genes. In this study, the efficacy of HSV vectors, G47Delta and NV1023 were examined for the treatment of the human breast cancer.

METHODS:

Human breast cancer MDA-MB-435 cells were cultured or implanted subcutaneously in BALB/c nude mice. The cells or tumors were inoculated with G47Delta or NV1023, and cell killing or inhibition of tumor growth determined. Both viruses contained the LacZ gene and expression in infected cells was detected with X-gal histochemistry.

RESULTS:

G47Delta and NV1023 were highly cytotoxic to MDA-MB-435 cells in vitro at very low multiplicities of infection. X-gal staining of infected tumor cells in vitro and in vivo illustrated the replication and spread of both viruses. G47Delta and NV1023 inoculation inhibited tumor growth and prolonged mouse survival. Both vectors behaved similarly.

CONCLUSIONS:

Oncolytic HSV vectors, G47Delta and NV1023, were extremely effective at killing human breast cancer cells in vitro and in tumor xenografts in vivo. This novel form of cancer therapy warrants further investigation and consideration of clinical application.

• Authors: Ren-bin Liu, Samuel D Rabkin
• Journal: Chinese medical journal (Chin Med J (Engl)) Vol. 118 Issue 4 Pg. 307-12 (Feb 20 2005) ISSN: 0366-6999 [Print] China
• PMID: 15740669 (Publication Type: Journal Article, Research Support, U.S. Gov't, Non-P.H.S.)

Topics

• Animals
• Female
• Genetic Therapy
• Genetic Vectors
• Humans
• Mammary Neoplasms, Experimental (pathology, therapy, virology)
• Mice
• Mice, Inbred BALB C
• Neoplasm Transplantation
• Simplexvirus (genetics, physiology)
• Transplantation, Heterologous
• Virus Replication